| abstract |
Abstract of the Disclosure Phellodendrine analogs represented by the following formula (I), (I) wherein A represents a group , wherein B represents a hydrogen atom, a lower alkyl group, or a lower acyl group, or A and B may form, together with the adjacent nitrogen atom, a substituted 1,2,3,4-tetrahydroisoquinolyl ring represented by the following formula, , wherein R11, R12, R21, R22, R31 and R32 individually represent a hydrogen atom, a hydroxy group, or a lower alkoxy group, n1 is a number 0-2, n2 is 1 or 2, and m1 denotes a number 0-1, provided that when A is a group , if n2 is 2, B is a lower acyl group, and further that when A and B together form a substituted 1,2,3,4-tetrahydroisoquinolyl ring, n1 is 1 and m1 is not 0. Since the phellodendrine analogs (I) and related compounds thereof exhibit an excellent allergy type IV suppressing action, they can be used as a drug effective for curing diseases involving allergy type IV, such as chronic hepatitis, intractable asthma, nephrotic syndrome, rheumatism, and the like. |